| dabigatran 150mg vs enoxaparin | No demonstrated result suggested Symptomatic deep-vein thrombosis by 789% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 8.89 [1.12 70.29] | p=0.04 | 0 | 2298 | 1 | RE-NOVATE (150mg), | | major VTE (fatal and non fatal DVT,PE) | 1.09 [0.68 1.74] | p=1.00 | 0 | 1805 | 1 | RE-NOVATE (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.28 [0.90 1.83] | p=1.00 | 0 | 1771 | 1 | RE-NOVATE (150mg), | | asymptomatic DVT | 1.15 [0.80 1.68] | p=1.00 | 0 | 1765 | 1 | RE-NOVATE (150mg), | | non-fatal pulmonary embolism | 0.33 [0.03 3.17] | p=1.00 | 0 | 2298 | 1 | RE-NOVATE (150mg), | | distal DVT | 1.50 [0.88 2.54] | p=1.00 | 0 | 1765 | 1 | RE-NOVATE (150mg), | | proximal DVT | 0.90 [0.54 1.51] | p=1.00 | 0 | 1799 | 1 | RE-NOVATE (150mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 0.98 [0.02 49.36] | p=1.00 | 0 | 2309 | 1 | RE-NOVATE (150mg), | | Major bleeding | 0.83 [0.41 1.65] | p=1.00 | 0 | 2317 | 1 | RE-NOVATE (150mg), | | any bleedings | no data | | Coronary event | 0.72 [0.31 1.69] | p=1.00 | 0 | 3463 | 1 | RE-NOVATE (150mg), | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin (europe regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 0.37 [0.10 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | major VTE (fatal and non fatal DVT,PE) | 1.08 [0.56 2.06] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.07 [0.84 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | asymptomatic DVT | 1.10 [0.86 1.41] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | non-fatal pulmonary embolism | 2.92 [0.12 71.85] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | distal DVT | 1.07 [0.83 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | proximal DVT | 1.03 [0.53 2.02] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 0.98 [0.06 15.77] | p=1.00 | 0 | 1381 | 1 | RE-MODEL (150mg), | | Major bleeding | 0.99 [0.39 2.50] | p=1.00 | 0 | 1397 | 1 | RE-MODEL (150mg), | | any bleedings | no data | | Coronary event | no data | | major or clinically relevant non-major bleeding | 1.22 [0.82 1.83] | p=1.00 | 0 | 1397 | 1 | RE-MODEL (150mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin (US regimen) | No demonstrated result suggested total VTE and all-cause mortality by 33% (not demonstrated) suggested distal DVT by 33% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | no data | | major VTE (fatal and non fatal DVT,PE) | 1.36 [0.69 2.68] | p=1.00 | 0 | 1324 | 1 | RE-MOBILIZE (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.33 [1.05 1.69] | p=0.04 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | asymptomatic DVT | no data | | non-fatal pulmonary embolism | 0.09 [0.00 1.63] | p=1.00 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | distal DVT | 1.33 [1.03 1.70] | p=0.04 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | proximal DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 3.00 [0.12 73.66] | p=1.00 | 0 | 1753 | 1 | RE-MOBILIZE (150mg), | | Major bleeding | 0.42 [0.15 1.18] | p=1.00 | 0 | 1739 | 1 | RE-MOBILIZE (150mg), | | any bleedings | no data | | Coronary event | no data | | major or clinically relevant non-major bleeding | 0.82 [0.49 1.37] | p=1.00 | 0 | 1739 | 1 | RE-MOBILIZE (150mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 6.03 [0.72 50.14] | p=1.00 | 0 | 2279 | 1 | RE-NOVATE (220mg), | | major VTE (fatal and non fatal DVT,PE) | 0.78 [0.47 1.30] | p=1.00 | 0 | 1826 | 1 | RE-NOVATE (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 0.90 [0.61 1.32] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | asymptomatic DVT | 0.73 [0.48 1.10] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | non-fatal pulmonary embolism | 1.70 [0.40 7.13] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | distal DVT | 0.94 [0.52 1.69] | p=1.00 | 0 | 1768 | 1 | RE-NOVATE (220mg), | | proximal DVT | 0.57 [0.32 1.02] | p=1.00 | 0 | 1819 | 1 | RE-NOVATE (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 7.03 [0.36 136.28] | p=1.00 | 0 | 2279 | 1 | RE-NOVATE (220mg), | | Major bleeding | 1.29 [0.69 2.40] | p=1.00 | 0 | 2300 | 1 | RE-NOVATE (220mg), | | any bleedings | no data | | Coronary event | 0.99 [0.06 15.90] | p=1.00 | 0 | 2013 | 1 | RE-NOVATE 2, | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin (europe regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 0.13 [0.02 1.02] | p=1.00 | 0 | 1360 | 1 | RE-MODEL (220mg), | | major VTE (fatal and non fatal DVT,PE) | 0.73 [0.35 1.50] | p=1.00 | 0 | 1017 | 1 | RE-MODEL (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 0.97 [0.75 1.25] | p=1.00 | 0 | 1015 | 1 | RE-MODEL (220mg), | | asymptomatic DVT | 1.00 [0.77 1.29] | p=1.00 | 0 | 1015 | 1 | RE-MODEL (220mg), | | non-fatal pulmonary embolism | no data | | distal DVT | 1.02 [0.78 1.32] | p=1.00 | 0 | 1014 | 1 | RE-MODEL (220mg), | | proximal DVT | 0.82 [0.39 1.73] | p=1.00 | 0 | 1013 | 1 | RE-MODEL (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 1.01 [0.06 16.26] | p=1.00 | 0 | 1360 | 1 | RE-MODEL (220mg), | | Major bleeding | 1.14 [0.46 2.81] | p=1.00 | 0 | 1373 | 1 | RE-MODEL (220mg), | | any bleedings | no data | | Coronary event | 1.26 [0.39 4.02] | p=1.00 | 0 | 2076 | 1 | RE-MODEL (220mg), | | major or clinically relevant non-major bleeding | 1.11 [0.73 1.68] | p=1.00 | 0 | 1373 | 1 | RE-MODEL (220mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin (US regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | no data | | major VTE (fatal and non fatal DVT,PE) | 1.51 [0.77 2.96] | p=1.00 | 0 | 1286 | 1 | RE-MOBILIZE (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.23 [0.96 1.57] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | asymptomatic DVT | no data | | non-fatal pulmonary embolism | no data | | distal DVT | 1.20 [0.93 1.55] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | proximal DVT | 1.49 [0.66 3.38] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | no data | | Major bleeding | 0.42 [0.15 1.20] | p=1.00 | 0 | 1725 | 1 | RE-MOBILIZE (220mg), | | any bleedings | no data | | Coronary event | 1.05 [0.47 2.33] | p=1.00 | 0 | 2586 | 1 | RE-MOBILIZE (220mg), | | major or clinically relevant non-major bleeding | 0.86 [0.51 1.43] | p=1.00 | 0 | 1725 | 1 | RE-MOBILIZE (220mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin | No demonstrated result suggested Symptomatic deep-vein thrombosis by 789% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 8.89 [1.12 70.29] | p=0.04 | 0 | 2298 | 1 | RE-NOVATE (150mg), | | major VTE (fatal and non fatal DVT,PE) | 1.09 [0.68 1.74] | p=1.00 | 0 | 1805 | 1 | RE-NOVATE (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.28 [0.90 1.83] | p=1.00 | 0 | 1771 | 1 | RE-NOVATE (150mg), | | asymptomatic DVT | 1.15 [0.80 1.68] | p=1.00 | 0 | 1765 | 1 | RE-NOVATE (150mg), | | non-fatal pulmonary embolism | 0.33 [0.03 3.17] | p=1.00 | 0 | 2298 | 1 | RE-NOVATE (150mg), | | distal DVT | 1.50 [0.88 2.54] | p=1.00 | 0 | 1765 | 1 | RE-NOVATE (150mg), | | proximal DVT | 0.90 [0.54 1.51] | p=1.00 | 0 | 1799 | 1 | RE-NOVATE (150mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 0.98 [0.02 49.36] | p=1.00 | 0 | 2309 | 1 | RE-NOVATE (150mg), | | Major bleeding | 0.83 [0.41 1.65] | p=1.00 | 0 | 2317 | 1 | RE-NOVATE (150mg), | | any bleedings | no data | | Coronary event | 0.72 [0.31 1.69] | p=1.00 | 0 | 3463 | 1 | RE-NOVATE (150mg), | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 6.03 [0.72 50.14] | p=1.00 | 0 | 2279 | 1 | RE-NOVATE (220mg), | | major VTE (fatal and non fatal DVT,PE) | 0.78 [0.47 1.30] | p=1.00 | 0 | 1826 | 1 | RE-NOVATE (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 0.90 [0.61 1.32] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | asymptomatic DVT | 0.73 [0.48 1.10] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | non-fatal pulmonary embolism | 1.70 [0.40 7.13] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | distal DVT | 0.94 [0.52 1.69] | p=1.00 | 0 | 1768 | 1 | RE-NOVATE (220mg), | | proximal DVT | 0.57 [0.32 1.02] | p=1.00 | 0 | 1819 | 1 | RE-NOVATE (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 7.03 [0.36 136.28] | p=1.00 | 0 | 2279 | 1 | RE-NOVATE (220mg), | | Major bleeding | 1.29 [0.69 2.40] | p=1.00 | 0 | 2300 | 1 | RE-NOVATE (220mg), | | any bleedings | no data | | Coronary event | 0.99 [0.06 15.90] | p=1.00 | 0 | 2013 | 1 | RE-NOVATE 2, | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin (europe regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 0.37 [0.10 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | major VTE (fatal and non fatal DVT,PE) | 1.08 [0.56 2.06] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.07 [0.84 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | asymptomatic DVT | 1.10 [0.86 1.41] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | non-fatal pulmonary embolism | 2.92 [0.12 71.85] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | distal DVT | 1.07 [0.83 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | proximal DVT | 1.03 [0.53 2.02] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 0.98 [0.06 15.77] | p=1.00 | 0 | 1381 | 1 | RE-MODEL (150mg), | | Major bleeding | 0.99 [0.39 2.50] | p=1.00 | 0 | 1397 | 1 | RE-MODEL (150mg), | | any bleedings | no data | | Coronary event | no data | | major or clinically relevant non-major bleeding | 1.22 [0.82 1.83] | p=1.00 | 0 | 1397 | 1 | RE-MODEL (150mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin (US regimen) | No demonstrated result suggested total VTE and all-cause mortality by 33% (not demonstrated) suggested distal DVT by 33% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | no data | | major VTE (fatal and non fatal DVT,PE) | 1.36 [0.69 2.68] | p=1.00 | 0 | 1324 | 1 | RE-MOBILIZE (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.33 [1.05 1.69] | p=0.04 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | asymptomatic DVT | no data | | non-fatal pulmonary embolism | 0.09 [0.00 1.63] | p=1.00 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | distal DVT | 1.33 [1.03 1.70] | p=0.04 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | proximal DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 3.00 [0.12 73.66] | p=1.00 | 0 | 1753 | 1 | RE-MOBILIZE (150mg), | | Major bleeding | 0.42 [0.15 1.18] | p=1.00 | 0 | 1739 | 1 | RE-MOBILIZE (150mg), | | any bleedings | no data | | Coronary event | no data | | major or clinically relevant non-major bleeding | 0.82 [0.49 1.37] | p=1.00 | 0 | 1739 | 1 | RE-MOBILIZE (150mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin (europe regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 0.13 [0.02 1.02] | p=1.00 | 0 | 1360 | 1 | RE-MODEL (220mg), | | major VTE (fatal and non fatal DVT,PE) | 0.73 [0.35 1.50] | p=1.00 | 0 | 1017 | 1 | RE-MODEL (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 0.97 [0.75 1.25] | p=1.00 | 0 | 1015 | 1 | RE-MODEL (220mg), | | asymptomatic DVT | 1.00 [0.77 1.29] | p=1.00 | 0 | 1015 | 1 | RE-MODEL (220mg), | | non-fatal pulmonary embolism | no data | | distal DVT | 1.02 [0.78 1.32] | p=1.00 | 0 | 1014 | 1 | RE-MODEL (220mg), | | proximal DVT | 0.82 [0.39 1.73] | p=1.00 | 0 | 1013 | 1 | RE-MODEL (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 1.01 [0.06 16.26] | p=1.00 | 0 | 1360 | 1 | RE-MODEL (220mg), | | Major bleeding | 1.14 [0.46 2.81] | p=1.00 | 0 | 1373 | 1 | RE-MODEL (220mg), | | any bleedings | no data | | Coronary event | 1.26 [0.39 4.02] | p=1.00 | 0 | 2076 | 1 | RE-MODEL (220mg), | | major or clinically relevant non-major bleeding | 1.11 [0.73 1.68] | p=1.00 | 0 | 1373 | 1 | RE-MODEL (220mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin (US regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | no data | | major VTE (fatal and non fatal DVT,PE) | 1.51 [0.77 2.96] | p=1.00 | 0 | 1286 | 1 | RE-MOBILIZE (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.23 [0.96 1.57] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | asymptomatic DVT | no data | | non-fatal pulmonary embolism | no data | | distal DVT | 1.20 [0.93 1.55] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | proximal DVT | 1.49 [0.66 3.38] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | no data | | Major bleeding | 0.42 [0.15 1.20] | p=1.00 | 0 | 1725 | 1 | RE-MOBILIZE (220mg), | | any bleedings | no data | | Coronary event | 1.05 [0.47 2.33] | p=1.00 | 0 | 2586 | 1 | RE-MOBILIZE (220mg), | | major or clinically relevant non-major bleeding | 0.86 [0.51 1.43] | p=1.00 | 0 | 1725 | 1 | RE-MOBILIZE (220mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin | No demonstrated result suggested Symptomatic deep-vein thrombosis by 789% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 8.89 [1.12 70.29] | p=0.04 | 0 | 2298 | 1 | RE-NOVATE (150mg), | | major VTE (fatal and non fatal DVT,PE) | 1.09 [0.68 1.74] | p=1.00 | 0 | 1805 | 1 | RE-NOVATE (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.28 [0.90 1.83] | p=1.00 | 0 | 1771 | 1 | RE-NOVATE (150mg), | | asymptomatic DVT | 1.15 [0.80 1.68] | p=1.00 | 0 | 1765 | 1 | RE-NOVATE (150mg), | | non-fatal pulmonary embolism | 0.33 [0.03 3.17] | p=1.00 | 0 | 2298 | 1 | RE-NOVATE (150mg), | | distal DVT | 1.50 [0.88 2.54] | p=1.00 | 0 | 1765 | 1 | RE-NOVATE (150mg), | | proximal DVT | 0.90 [0.54 1.51] | p=1.00 | 0 | 1799 | 1 | RE-NOVATE (150mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 0.98 [0.02 49.36] | p=1.00 | 0 | 2309 | 1 | RE-NOVATE (150mg), | | Major bleeding | 0.83 [0.41 1.65] | p=1.00 | 0 | 2317 | 1 | RE-NOVATE (150mg), | | any bleedings | no data | | Coronary event | 0.72 [0.31 1.69] | p=1.00 | 0 | 3463 | 1 | RE-NOVATE (150mg), | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin (europe regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 0.37 [0.10 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | major VTE (fatal and non fatal DVT,PE) | 1.08 [0.56 2.06] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.07 [0.84 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | asymptomatic DVT | 1.10 [0.86 1.41] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | non-fatal pulmonary embolism | 2.92 [0.12 71.85] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | distal DVT | 1.07 [0.83 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | proximal DVT | 1.03 [0.53 2.02] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 0.98 [0.06 15.77] | p=1.00 | 0 | 1381 | 1 | RE-MODEL (150mg), | | Major bleeding | 0.99 [0.39 2.50] | p=1.00 | 0 | 1397 | 1 | RE-MODEL (150mg), | | any bleedings | no data | | Coronary event | no data | | major or clinically relevant non-major bleeding | 1.22 [0.82 1.83] | p=1.00 | 0 | 1397 | 1 | RE-MODEL (150mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin (US regimen) | No demonstrated result suggested total VTE and all-cause mortality by 33% (not demonstrated) suggested distal DVT by 33% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | no data | | major VTE (fatal and non fatal DVT,PE) | 1.36 [0.69 2.68] | p=1.00 | 0 | 1324 | 1 | RE-MOBILIZE (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.33 [1.05 1.69] | p=0.04 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | asymptomatic DVT | no data | | non-fatal pulmonary embolism | 0.09 [0.00 1.63] | p=1.00 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | distal DVT | 1.33 [1.03 1.70] | p=0.04 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | proximal DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 3.00 [0.12 73.66] | p=1.00 | 0 | 1753 | 1 | RE-MOBILIZE (150mg), | | Major bleeding | 0.42 [0.15 1.18] | p=1.00 | 0 | 1739 | 1 | RE-MOBILIZE (150mg), | | any bleedings | no data | | Coronary event | no data | | major or clinically relevant non-major bleeding | 0.82 [0.49 1.37] | p=1.00 | 0 | 1739 | 1 | RE-MOBILIZE (150mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 6.03 [0.72 50.14] | p=1.00 | 0 | 2279 | 1 | RE-NOVATE (220mg), | | major VTE (fatal and non fatal DVT,PE) | 0.78 [0.47 1.30] | p=1.00 | 0 | 1826 | 1 | RE-NOVATE (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 0.90 [0.61 1.32] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | asymptomatic DVT | 0.73 [0.48 1.10] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | non-fatal pulmonary embolism | 1.70 [0.40 7.13] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | distal DVT | 0.94 [0.52 1.69] | p=1.00 | 0 | 1768 | 1 | RE-NOVATE (220mg), | | proximal DVT | 0.57 [0.32 1.02] | p=1.00 | 0 | 1819 | 1 | RE-NOVATE (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 7.03 [0.36 136.28] | p=1.00 | 0 | 2279 | 1 | RE-NOVATE (220mg), | | Major bleeding | 1.29 [0.69 2.40] | p=1.00 | 0 | 2300 | 1 | RE-NOVATE (220mg), | | any bleedings | no data | | Coronary event | 0.99 [0.06 15.90] | p=1.00 | 0 | 2013 | 1 | RE-NOVATE 2, | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin (europe regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 0.13 [0.02 1.02] | p=1.00 | 0 | 1360 | 1 | RE-MODEL (220mg), | | major VTE (fatal and non fatal DVT,PE) | 0.73 [0.35 1.50] | p=1.00 | 0 | 1017 | 1 | RE-MODEL (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 0.97 [0.75 1.25] | p=1.00 | 0 | 1015 | 1 | RE-MODEL (220mg), | | asymptomatic DVT | 1.00 [0.77 1.29] | p=1.00 | 0 | 1015 | 1 | RE-MODEL (220mg), | | non-fatal pulmonary embolism | no data | | distal DVT | 1.02 [0.78 1.32] | p=1.00 | 0 | 1014 | 1 | RE-MODEL (220mg), | | proximal DVT | 0.82 [0.39 1.73] | p=1.00 | 0 | 1013 | 1 | RE-MODEL (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 1.01 [0.06 16.26] | p=1.00 | 0 | 1360 | 1 | RE-MODEL (220mg), | | Major bleeding | 1.14 [0.46 2.81] | p=1.00 | 0 | 1373 | 1 | RE-MODEL (220mg), | | any bleedings | no data | | Coronary event | 1.26 [0.39 4.02] | p=1.00 | 0 | 2076 | 1 | RE-MODEL (220mg), | | major or clinically relevant non-major bleeding | 1.11 [0.73 1.68] | p=1.00 | 0 | 1373 | 1 | RE-MODEL (220mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin (US regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | no data | | major VTE (fatal and non fatal DVT,PE) | 1.51 [0.77 2.96] | p=1.00 | 0 | 1286 | 1 | RE-MOBILIZE (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.23 [0.96 1.57] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | asymptomatic DVT | no data | | non-fatal pulmonary embolism | no data | | distal DVT | 1.20 [0.93 1.55] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | proximal DVT | 1.49 [0.66 3.38] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | no data | | Major bleeding | 0.42 [0.15 1.20] | p=1.00 | 0 | 1725 | 1 | RE-MOBILIZE (220mg), | | any bleedings | no data | | Coronary event | 1.05 [0.47 2.33] | p=1.00 | 0 | 2586 | 1 | RE-MOBILIZE (220mg), | | major or clinically relevant non-major bleeding | 0.86 [0.51 1.43] | p=1.00 | 0 | 1725 | 1 | RE-MOBILIZE (220mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin | No demonstrated result suggested Symptomatic deep-vein thrombosis by 789% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 8.89 [1.12 70.29] | p=0.04 | 0 | 2298 | 1 | RE-NOVATE (150mg), | | major VTE (fatal and non fatal DVT,PE) | 1.09 [0.68 1.74] | p=1.00 | 0 | 1805 | 1 | RE-NOVATE (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.28 [0.90 1.83] | p=1.00 | 0 | 1771 | 1 | RE-NOVATE (150mg), | | asymptomatic DVT | 1.15 [0.80 1.68] | p=1.00 | 0 | 1765 | 1 | RE-NOVATE (150mg), | | non-fatal pulmonary embolism | 0.33 [0.03 3.17] | p=1.00 | 0 | 2298 | 1 | RE-NOVATE (150mg), | | distal DVT | 1.50 [0.88 2.54] | p=1.00 | 0 | 1765 | 1 | RE-NOVATE (150mg), | | proximal DVT | 0.90 [0.54 1.51] | p=1.00 | 0 | 1799 | 1 | RE-NOVATE (150mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 0.98 [0.02 49.36] | p=1.00 | 0 | 2309 | 1 | RE-NOVATE (150mg), | | Major bleeding | 0.83 [0.41 1.65] | p=1.00 | 0 | 2317 | 1 | RE-NOVATE (150mg), | | any bleedings | no data | | Coronary event | 0.72 [0.31 1.69] | p=1.00 | 0 | 3463 | 1 | RE-NOVATE (150mg), | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin (europe regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 0.37 [0.10 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | major VTE (fatal and non fatal DVT,PE) | 1.08 [0.56 2.06] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.07 [0.84 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | asymptomatic DVT | 1.10 [0.86 1.41] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | non-fatal pulmonary embolism | 2.92 [0.12 71.85] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | distal DVT | 1.07 [0.83 1.38] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | proximal DVT | 1.03 [0.53 2.02] | p=1.00 | 0 | 1038 | 1 | RE-MODEL (150mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 0.98 [0.06 15.77] | p=1.00 | 0 | 1381 | 1 | RE-MODEL (150mg), | | Major bleeding | 0.99 [0.39 2.50] | p=1.00 | 0 | 1397 | 1 | RE-MODEL (150mg), | | any bleedings | no data | | Coronary event | no data | | major or clinically relevant non-major bleeding | 1.22 [0.82 1.83] | p=1.00 | 0 | 1397 | 1 | RE-MODEL (150mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 150mg vs enoxaparin (US regimen) | No demonstrated result suggested total VTE and all-cause mortality by 33% (not demonstrated) suggested distal DVT by 33% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | no data | | major VTE (fatal and non fatal DVT,PE) | 1.36 [0.69 2.68] | p=1.00 | 0 | 1324 | 1 | RE-MOBILIZE (150mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.33 [1.05 1.69] | p=0.04 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | asymptomatic DVT | no data | | non-fatal pulmonary embolism | 0.09 [0.00 1.63] | p=1.00 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | distal DVT | 1.33 [1.03 1.70] | p=0.04 | 0 | 1292 | 1 | RE-MOBILIZE (150mg), | | proximal DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 3.00 [0.12 73.66] | p=1.00 | 0 | 1753 | 1 | RE-MOBILIZE (150mg), | | Major bleeding | 0.42 [0.15 1.18] | p=1.00 | 0 | 1739 | 1 | RE-MOBILIZE (150mg), | | any bleedings | no data | | Coronary event | no data | | major or clinically relevant non-major bleeding | 0.82 [0.49 1.37] | p=1.00 | 0 | 1739 | 1 | RE-MOBILIZE (150mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 6.03 [0.72 50.14] | p=1.00 | 0 | 2279 | 1 | RE-NOVATE (220mg), | | major VTE (fatal and non fatal DVT,PE) | 0.78 [0.47 1.30] | p=1.00 | 0 | 1826 | 1 | RE-NOVATE (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 0.90 [0.61 1.32] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | asymptomatic DVT | 0.73 [0.48 1.10] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | non-fatal pulmonary embolism | 1.70 [0.40 7.13] | p=1.00 | 0 | 1777 | 1 | RE-NOVATE (220mg), | | distal DVT | 0.94 [0.52 1.69] | p=1.00 | 0 | 1768 | 1 | RE-NOVATE (220mg), | | proximal DVT | 0.57 [0.32 1.02] | p=1.00 | 0 | 1819 | 1 | RE-NOVATE (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 7.03 [0.36 136.28] | p=1.00 | 0 | 2279 | 1 | RE-NOVATE (220mg), | | Major bleeding | 1.29 [0.69 2.40] | p=1.00 | 0 | 2300 | 1 | RE-NOVATE (220mg), | | any bleedings | no data | | Coronary event | 0.99 [0.06 15.90] | p=1.00 | 0 | 2013 | 1 | RE-NOVATE 2, | | major or clinically relevant non-major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin (europe regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | 0.13 [0.02 1.02] | p=1.00 | 0 | 1360 | 1 | RE-MODEL (220mg), | | major VTE (fatal and non fatal DVT,PE) | 0.73 [0.35 1.50] | p=1.00 | 0 | 1017 | 1 | RE-MODEL (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 0.97 [0.75 1.25] | p=1.00 | 0 | 1015 | 1 | RE-MODEL (220mg), | | asymptomatic DVT | 1.00 [0.77 1.29] | p=1.00 | 0 | 1015 | 1 | RE-MODEL (220mg), | | non-fatal pulmonary embolism | no data | | distal DVT | 1.02 [0.78 1.32] | p=1.00 | 0 | 1014 | 1 | RE-MODEL (220mg), | | proximal DVT | 0.82 [0.39 1.73] | p=1.00 | 0 | 1013 | 1 | RE-MODEL (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | 1.01 [0.06 16.26] | p=1.00 | 0 | 1360 | 1 | RE-MODEL (220mg), | | Major bleeding | 1.14 [0.46 2.81] | p=1.00 | 0 | 1373 | 1 | RE-MODEL (220mg), | | any bleedings | no data | | Coronary event | 1.26 [0.39 4.02] | p=1.00 | 0 | 2076 | 1 | RE-MODEL (220mg), | | major or clinically relevant non-major bleeding | 1.11 [0.73 1.68] | p=1.00 | 0 | 1373 | 1 | RE-MODEL (220mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| dabigatran 220mg vs enoxaparin (US regimen) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Symptomatic deep-vein thrombosis | no data | | major VTE (fatal and non fatal DVT,PE) | 1.51 [0.77 2.96] | p=1.00 | 0 | 1286 | 1 | RE-MOBILIZE (220mg), | | Deep vein thrombosis | no data | | total VTE and all-cause mortality | 1.23 [0.96 1.57] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | asymptomatic DVT | no data | | non-fatal pulmonary embolism | no data | | distal DVT | 1.20 [0.93 1.55] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | proximal DVT | 1.49 [0.66 3.38] | p=1.00 | 0 | 1247 | 1 | RE-MOBILIZE (220mg), | | Symptomatic venous thromboembolism (DVT, PE) | no data | | myocardial infarction (fatal and non fatal) | no data | | All cause death | no data | | Major bleeding | 0.42 [0.15 1.20] | p=1.00 | 0 | 1725 | 1 | RE-MOBILIZE (220mg), | | any bleedings | no data | | Coronary event | 1.05 [0.47 2.33] | p=1.00 | 0 | 2586 | 1 | RE-MOBILIZE (220mg), | | major or clinically relevant non-major bleeding | 0.86 [0.51 1.43] | p=1.00 | 0 | 1725 | 1 | RE-MOBILIZE (220mg), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
